Teva (TEVA) Pharmaceuticals will postpone launching its version of Indivior’s opioid addiction drug until the resolution of a U.S. court case on different generic rival, according to Reuters. Dr.Reddy’s Laboratories (RDY) is engaged in a legal battle in the United States to re-launch a generic version of the Indivior’s Suboxone Film. Indivior expects full-year net revenues of $25M-$50M from its opioid addiction drug Sublocade
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.